Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
Clinical trial NCT02622074 · COMPLETED
Trial details
- NCT number
- NCT02622074
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-27
- Primary completion
- 2018-05-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.